We create innovative treatments for nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. Our lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen is evaluating a new discovery lead, NVG-300, in a preclinical model of ischemic stroke and confirmatory SCI study.

Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury

NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.

For information regarding recruitment, the call center phone number is +1 (855) 559-6902. 

View our Corporate Presentation

Stay Connected

Subscribe to our mailing list to stay up to date

The Latest

News Release

June 2, 2025

NervGen announced positive topline results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial of NVG-291 as a potential treatment for spinal cord injury.  

News Release

May 15, 2025

NervGen reported its financial and operational results for the first quarter ended March 31, 2025.  

NEWS RELEASE

April 3, 2024

NervGen reported its financial and operational results for the full year ended December 31, 2024.